The role of MACF1 on acute myeloid leukemia cell proliferation is involved in Runx2-targeted PI3K/Akt signaling
- PMID: 35857251
- DOI: 10.1007/s11010-022-04517-x
The role of MACF1 on acute myeloid leukemia cell proliferation is involved in Runx2-targeted PI3K/Akt signaling
Abstract
Acute myeloid leukemia (AML) is a type of hematologic diseases, which is related to abnormal genes. The aberrant microtubule actin cross-linking factor 1 (MACF1) is associated with progression of multiple tumors by initiating cell proliferation. Nevertheless, the function and action mechanism of MACF1 in AML cell proliferation remain mostly unknown. Our study aimed to explore the influence of MACF1 on AML cell proliferation by CCK-8 and EdU staining assays. Moreover, we aimed to explore the effect of MACF1 on downstream Runx2 and the PI3K/Akt signaling. MACF1 expression in AML patients was predicted by bioinformatics analysis. Cells were transfected with si-con, si-MACF1 or Runx2 using Lipofectamine 2000. Upregulated MACF1 was found in AML patients and predicted worse overall survival. MACF1 expression was upregulated in AML cells compared with that in hematopoietic stem and progenitor cells. MACF1 silencing reduced AML cell proliferation. Runx2 level was increased in AML cells, and decreased by silencing MACF1. Runx2 upregulation rescued MACF1 silencing-mediated inhibition of proliferation. MACF1 downregulation inhibited activation of the PI3K/Akt pathway by decreasing Runx2. Activation of the PI3K/Akt pathway abrogated the suppressive role of MACF1 downregulation in AML cell proliferation. In conclusion, MACF1 knockdown decreased AML cell proliferation by reducing Runx2 and inactivating the PI3K/Akt signaling.
Keywords: Acute myeloid leukemia; MACF1; PI3K/Akt; Proliferation; Runx2.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
LRRC1 knockdown downregulates MACF1 to inhibit the malignant progression of acute myeloid leukemia by inactivating β-catenin/c-Myc signaling.J Mol Histol. 2024 Feb;55(1):37-50. doi: 10.1007/s10735-023-10170-5. Epub 2024 Jan 2. J Mol Histol. 2024. PMID: 38165568
-
miR-338-3p Plays a Significant Role in Casticin-Induced Suppression of Acute Myeloid Leukemia via Targeting PI3K/Akt Pathway.Biomed Res Int. 2022 Jun 18;2022:9214130. doi: 10.1155/2022/9214130. eCollection 2022. Biomed Res Int. 2022. PMID: 35765408 Free PMC article.
-
Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.J Transl Med. 2022 Dec 22;20(1):612. doi: 10.1186/s12967-022-03831-8. J Transl Med. 2022. PMID: 36550462 Free PMC article.
-
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.Int J Mol Sci. 2020 Apr 21;21(8):2907. doi: 10.3390/ijms21082907. Int J Mol Sci. 2020. PMID: 32326335 Free PMC article. Review.
-
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.Curr Med Chem. 2007;14(19):2009-23. doi: 10.2174/092986707781368423. Curr Med Chem. 2007. PMID: 17691943 Review.
Cited by
-
High-altitude hypoxia exacerbates chemotherapy-induced myelosuppression by lowering serum G-CSF/GM-CSF and regulating apoptosis and proliferation.Discov Oncol. 2025 May 28;16(1):938. doi: 10.1007/s12672-025-02611-2. Discov Oncol. 2025. PMID: 40434597 Free PMC article.
-
Concurrent de novo MACF1 mutation and inherited 16p13.11 microduplication in a preterm newborn with hypotonia, joint hyperlaxity and multiple congenital malformations: a case report.BMC Pediatr. 2024 Aug 16;24(1):528. doi: 10.1186/s12887-024-04628-y. BMC Pediatr. 2024. PMID: 39152427 Free PMC article.
-
LRRC1 knockdown downregulates MACF1 to inhibit the malignant progression of acute myeloid leukemia by inactivating β-catenin/c-Myc signaling.J Mol Histol. 2024 Feb;55(1):37-50. doi: 10.1007/s10735-023-10170-5. Epub 2024 Jan 2. J Mol Histol. 2024. PMID: 38165568
-
Microtubule actin crosslinking factor 1, a brain tumor oncoprotein (Review).Mol Clin Oncol. 2024 Dec 3;22(2):15. doi: 10.3892/mco.2024.2810. eCollection 2025 Feb. Mol Clin Oncol. 2024. PMID: 39720461 Free PMC article. Review.
-
IRF1 is a core transcriptional regulatory circuitry member promoting AML progression by regulating lipid metabolism.Exp Hematol Oncol. 2025 Mar 1;14(1):25. doi: 10.1186/s40164-025-00612-z. Exp Hematol Oncol. 2025. PMID: 40025540 Free PMC article.
References
-
- Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J 103(3):38–40
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical